Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › STEP-HFpEF DM

STEP-HFpEF DM

Semaglutide · HFpEF + obesity + T2D

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
HFpEF + obesity + T2D
Official title
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
completed · 2021-06 → 2023-10
Participants
617
Duration
52 weeks
Registry
NCT04916470

Outcomes in the indication

STEP-HFpEF DM Semaglutide · HFpEF + obesity + T2D · 52 weeks · n = 616 seed

KCCQ-CSS +7.3 points vs placebo

MeasureDrugControlDifference (95 % CI)Status
Body weight, percent change from baseline
week 52
−9.8−3.4−6.4 (−7.6 to −5.2) percentage pointsverified
KCCQ clinical summary score, change from baseline
week 52
+13.7+6.4+7.3 (+4.1 to +10.4) points (0-100)verified
Verbatim quotes (2)
  • Body weight, percent change from baseline
    the mean percentage change in body weight was -9.8% with semaglutide and -3.4% with placebo (estimated difference, -6.4 percentage points; 95% CI, -7.6 to -5.2; P<0.001)
  • KCCQ clinical summary score, change from baseline
    The mean change in the KCCQ-CSS was 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: STEP-HFpEF DM. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-hfpef-dm/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.